{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T17:26:10Z","timestamp":1769880370054,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T00:00:00Z","timestamp":1559865600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T00:00:00Z","timestamp":1559865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s10072-019-03959-4","type":"journal-article","created":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T20:02:13Z","timestamp":1559937733000},"page":"2119-2124","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Four cases of natalizumab-related PML: a less severe course in extended interval dosing?"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4126-426X","authenticated-orcid":false,"given":"Cristina","family":"Scarpazza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"De Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulietta","family":"Tabiadon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Vittoria","family":"Turrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simonetta","family":"Gerevini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruggero","family":"Capra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,7]]},"reference":[{"issue":"9","key":"3959_CR1","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW, AFFIRM Investigators (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899\u2013910","journal-title":"N Engl J Med"},{"issue":"5","key":"3959_CR2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S1474-4422(18)30040-1","volume":"17","author":"EO Major","year":"2018","unstructured":"Major EO, Yousry TA, Clifford DB (2018) Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. Lancet Neurol 17(5):467\u2013480","journal-title":"Lancet Neurol"},{"issue":"11","key":"3959_CR3","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","volume":"16","author":"PR Ho","year":"2017","unstructured":"Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I (2017) Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol 16(11):925\u2013933","journal-title":"Lancet Neurol"},{"issue":"6","key":"3959_CR4","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1177\/1352458517708464","volume":"24","author":"ZL van Kempen","year":"2018","unstructured":"van Kempen ZL, Leurs CE, Witte BI, de Vries A, Wattjes MP, Rispens T, Killestein J (2018) The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing. Mult Scler 24(6):805\u2013810","journal-title":"Mult Scler"},{"issue":"8","key":"3959_CR5","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1136\/jnnp-2015-312940","volume":"87","author":"L Zhovtis Ryerson","year":"2016","unstructured":"Zhovtis Ryerson L, Frohman TC, Foley J, Kister I, Weinstock-Guttman B, Tornatore C, Pandey K, Donnelly S, Pawate S, Bomprezzi R, Smith D, Kolb C, Qureshi S, Okuda D, Kalina J, Rimler Z, Green R, Monson N, Hoyt T, Bradshaw M, Fallon J, Chamot E, Bucello M, Beh S, Cutter G, Major E, Herbert J, Frohman EM (2016) Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry 87(8):885\u2013889","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3959_CR6","unstructured":"Zhovtis Ryerson L et al. (2018) Natalizumab extended interval dosing is associated with a reduction in progressive multifocal leukoencephalopathy risk in the TOUCH registry. ACTRIMS Forum 2018, Oral and Poster Presentation."},{"issue":"5","key":"3959_CR7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2217\/nmt.15.42","volume":"5","author":"JV Hervas","year":"2015","unstructured":"Hervas JV et al (2015) Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen. Neurodegener Dis Manag 5(5):399\u2013402","journal-title":"Neurodegener Dis Manag"},{"issue":"5","key":"3959_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/1756285614540224","volume":"7","author":"R Bomprezzi","year":"2014","unstructured":"Bomprezzi R, Pawate S (2014) Extended interval dosing of natalizumab: a two-center, 7-year experience. Ther Adv Neurol Disord 7(5):227\u2013231","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"3959_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/CPJ.0000000000000457","volume":"8","author":"LE Baldassari","year":"2018","unstructured":"Baldassari LE, Jones SE, Clifford DB, Fox RJ (2018) Progressive multifocal leukoencephalopathy with extended natalizumab dosing. Neurol Clin Pract 8(3):1\u20133","journal-title":"Neurol Clin Pract"},{"issue":"12","key":"3959_CR10","doi-asserted-by":"publisher","first-page":"e0168376","DOI":"10.1371\/journal.pone.0168376","volume":"11","author":"L Prosperini","year":"2016","unstructured":"Prosperini L, de Rossi N, Scarpazza C, Moiola L, Cosottini M, Gerevini S, Capra R, on behalf of the Italian PML study group (2016) Natalizumab-related progressive multifocal leukoencephalopathy in multiple sclerosis: findings from an Italian independent registry. PLoS One 11(12):e0168376","journal-title":"PLoS One"},{"key":"3959_CR11","unstructured":"Gagnier JJ et al (2013) The CARE guidelines: consensus-based clinical case reporting guideline development. BMJ Case Rep 2(5):38\u201343"},{"issue":"2","key":"3959_CR12","first-page":"1","volume":"2","author":"C Scarpazza","year":"2017","unstructured":"Scarpazza C et al (2017) The still under-investigated role of cognitive deficits in PML diagnosis. MS Demyel Disord 2(2):1\u20139","journal-title":"MS Demyel Disord"},{"issue":"10","key":"3959_CR13","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/acn3.114","volume":"1","author":"T Dong-Si","year":"2014","unstructured":"Dong-Si T, Richman S, Wattjes MP, Wenten M, Gheuens S, Philip J, Datta S, McIninch J, Bozic C, Bloomgren G, Richert N (2014) Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann Clin Transl Neurol 1(10):755\u2013764","journal-title":"Ann Clin Transl Neurol"},{"issue":"15","key":"3959_CR14","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","volume":"80","author":"JR Berger","year":"2013","unstructured":"Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ, Bartt R, Major EO, Nath A (2013) PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 80(15):1430\u20131438","journal-title":"Neurology"},{"key":"3959_CR15","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jamaneurol.2018.0094","volume":"75","author":"MT Wijburg","year":"2018","unstructured":"Wijburg MT, Kleerekooper I, Lissenberg-Witte BI, de Vos M, Warnke C, Uitdehaag BMJ, Barkhof F, Killestein J, Wattjes MP (2018) Association of progressive multifocal leukoencephalopathy lesion volume with JC virus polymerase chain reaction results in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. JAMA Neurol 75:827\u2013833","journal-title":"JAMA Neurol"},{"key":"3959_CR16","doi-asserted-by":"crossref","unstructured":"Wijburg MT et al (2019) Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort. J Neurol Neurosurg Psychiatry 90(1):44\u201346","DOI":"10.1136\/jnnp-2018-318261"},{"issue":"5","key":"3959_CR17","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ana.25070","volume":"82","author":"C Scarpazza","year":"2017","unstructured":"Scarpazza C, Prosperini L, de Rossi N, Moiola L, Sormani MP, Gerevini S, Capra R, on behalf of the Italian PML group (2017) To do or not to do? Plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy. Ann Neurol 82(5):697\u2013705","journal-title":"Ann Neurol"},{"issue":"5","key":"3959_CR18","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1136\/jnnp-2017-316886","volume":"89","author":"MP Wattjes","year":"2018","unstructured":"Wattjes MP, Wijburg MT, van Eijk J, Frequin S, Uitdehaag BMJ, Barkhof F, Warnke C, Killestein J (2018) Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS. J Neurol Neurosurg Psychiatry 89(5):535\u2013541","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"3959_CR19","first-page":"117","volume":"87","author":"C McGuigan","year":"2016","unstructured":"McGuigan C et al (2016) Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry 87(2):117\u2013125","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"3959_CR20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1136\/jnnp-2018-319208","volume":"90","author":"C Scarpazza","year":"2019","unstructured":"Scarpazza C, Signori A, Prosperini L, Sormani MP, Cosottini M, Capra R, Gerevini S (2019) Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution. J Neurol Neurosurg Psychiatry 90(3):261\u2013267","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"3959_CR21","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1212\/WNL.0000000000003740","volume":"88","author":"D Landi","year":"2017","unstructured":"Landi D, de Rossi N, Zagaglia S, Scarpazza C, Prosperini L, Albanese M, Buttari F, Mori F, Marfia GA, Sormani MP, Capra R, Centonze D, Italian PML study group (2017) No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology 88(12):1144\u20131152","journal-title":"Neurology"},{"issue":"17","key":"3959_CR22","first-page":"1694","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Belachew S, Kappos L (2017) Ocrelizumab in primary progressive and relapsing multiple sclerosis. N Engl J Med 376(17):1694","journal-title":"N Engl J Med"},{"issue":"3","key":"3959_CR23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.autrev.2018.09.012","volume":"18","author":"J Sellner","year":"2019","unstructured":"Sellner J, Rommer PS (2019) A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis. Autoimmun Rev 18(3):255\u2013261","journal-title":"Autoimmun Rev"},{"issue":"12","key":"3959_CR24","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1007\/s00415-017-8594-9","volume":"264","author":"G Pardo","year":"2017","unstructured":"Pardo G, Jones DE (2017) The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. J Neurol 264(12):2351\u20132374","journal-title":"J Neurol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-019-03959-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-019-03959-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-019-03959-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T23:15:42Z","timestamp":1591398942000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-019-03959-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,7]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["3959"],"URL":"https:\/\/doi.org\/10.1007\/s10072-019-03959-4","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,7]]},"assertion":[{"value":"29 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Patients provided written informed consent for the publication of data. Retrospective analysis of patients\u2019 data was approved by the ethical committee of the Spedali Civili of Brescia.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"Dr. Scarpazza, Dr. Tabiadon, and Dr. Turrini have no conflicts of interest. Dr. De Rossi received consulting fees from Biogen, Merk-Serono, and Genzyme. Dr. Gerevini declares consulting fees or honorarium from Novartis and Biogen and payment for lectures including service on speaker bureaus from Novartis and Biogen. Dr. Capra received payment for lectures from Novartis, Biogen, and Genzyme.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}